{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:57:41Z","timestamp":1787695061046,"version":"build-2784847793"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1053\/j.semnuclmed.2025.11.006","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T12:14:34Z","timestamp":1764418474000},"page":"152-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Any Role of FDG PET in Renal Cancer?"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-1234","authenticated-orcid":false,"given":"Yoshiko","family":"Ueno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4846-5662","authenticated-orcid":false,"given":"Munenobu","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Sofue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7782-548X","authenticated-orcid":false,"given":"Takamichi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0001","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1007\/s11604-024-01593-5","article-title":"Efficacy of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography for detecting renal cell carcinoma in patients with end-stage renal disease","volume":"42","author":"Hirasawa","year":"2024","journal-title":"Jpn J Radiol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.006_bib0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13550-025-01206-w","article-title":"Diagnostic and prognostic role of 18F-FDG PET\/CT for sarcomatoid differentiation in renal cell carcinoma","volume":"15","author":"Na","year":"2025","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0003","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fonc.2016.00201","article-title":"The place of FDG PET\/CT in renal cell carcinoma: value and limitations","volume":"6","author":"Liu","year":"2016","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0004","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.006_bib0005","article-title":"Metabolic reprogramming of clear cell renal cell carcinoma","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0006","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/RLU.0000000000000875","article-title":"Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET\/CT","volume":"40","author":"Takahashi","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0007","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1007\/s00330-017-4875-z","article-title":"Evaluation of renal cell carcinoma histological subtype and Fuhrman grade using 18F-fluorodeoxyglucose positron emission tomography\/computed tomography","volume":"27","author":"Nakajima","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0008","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00259-020-04996-4","article-title":"2-[18F] FDG PET\/CT parameters associated with WHO\/ISUP grade in clear cell renal cell carcinoma","volume":"48","author":"Zhao","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40644-021-00393-8","article-title":"Clinical utility of FDG PET\/CT for primary and recurrent papillary renal cell carcinoma","volume":"21","author":"Hou","year":"2021","journal-title":"Cancer Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1282508","article-title":"Renal cell oncocytoma tumor evolutions: a case report","volume":"14","author":"Alduraibi","year":"2024","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0011","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3892\/ol.2013.1739","article-title":"Collecting duct carcinoma of the kidney: imaging observations of a rare tumor","volume":"7","author":"Hu","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0012","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.crad.2012.02.012","article-title":"Distal ureteral seeding metastasis of collecting duct carcinoma manifesting as deep vein thrombosis","volume":"67","author":"Yang","year":"2012","journal-title":"Clin Radiol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.006_bib0013","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s11604-025-01761-1","article-title":"Role of 18F-FDG-PET in renal tumors: insights from WHO 2022 classification","volume":"43","author":"Hirota","year":"2025","journal-title":"Jpn J Radiol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.006_bib0014","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10157-010-0347-3","article-title":"Imaging of acquired cystic disease-associated renal cell carcinoma by contrast-enhanced ultrasonography with perflubutane microbubbles and positron emission tomography-computed tomography","volume":"15","author":"Ishikawa","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11604-018-0789-1","article-title":"Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison 11C-choline and FDG PET\/CT with dynamic contrast-enhanced CT","volume":"37","author":"Kitajima","year":"2019","journal-title":"Jpn J Radiol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.006_bib0016","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s11604-022-01294-x","article-title":"Mucinous tubular and spindle cell carcinomas of the kidney (MTSCC-Ks): CT and MR imaging characteristics","volume":"40","author":"Kang","year":"2022","journal-title":"Jpn J Radiol"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0017","article-title":"Mucinous tubular and spindle cell carcinoma of the kidney: a study of clinical, imaging features and treatment outcomes","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0018","doi-asserted-by":"crossref","first-page":"37","DOI":"10.25259\/JCIS_93_2024","article-title":"Multimodal imaging findings of tubulocystic renal cell carcinoma: a case report","volume":"14","author":"Chen","year":"2024","journal-title":"J Clin Imaging Sci"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.006_bib0019","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3348\/jksr.2011.65.3.285","article-title":"Tubulocystic carcinoma of the kidney with bone metastasis: a case report","volume":"65","author":"Im","year":"2011","journal-title":"J Korean Soc Radiol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.006_bib0020","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1186\/s12885-025-15065-0","article-title":"Imaging features of eosinophilic solid and cystic renal cell carcinoma","volume":"25","author":"Ling","year":"2025","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.006_bib0021","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/RLU.0000000000004282","article-title":"FDG PET\/CT in eosinophilic solid and cystic renal cell carcinoma with lung metastases","volume":"47","author":"Zhang","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0022","doi-asserted-by":"crossref","first-page":"61","DOI":"10.15586\/jkcvhl.v10i3.266","article-title":"Case reports of TFE3-rearranged renal cell carcinoma: FDG-PET uptake might help diagnosis","volume":"10","author":"Murakami","year":"2023","journal-title":"J Kidney Cancer VHL"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40644-021-00392-9","article-title":"Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study","volume":"21","author":"Nikolovski","year":"2021","journal-title":"Cancer Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1073728","article-title":"Surgical and oncological management of renal medullary carcinoma in a young patient: a case report","volume":"13","author":"Courcier","year":"2023","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3348\/kjr.2013.14.2.337","article-title":"FDG PET or PET\/CT in evaluation of renal angiomyolipoma","volume":"14","author":"Lin","year":"2013","journal-title":"Korean J Radiol"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0026","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/RLU.0b013e3181abb6cf","article-title":"Visualization of renal angiomyolipoma on F-18 FDG PET\/CT","volume":"34","author":"Arnold","year":"2009","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.006_bib0027","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.clgc.2019.10.028","article-title":"Giant epithelioid angiomyolipoma: an imaging-related differential diagnosis among fat-containing renal masses","volume":"18","author":"Galatola","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.006_bib0028","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/RLU.0b013e318266cde2","article-title":"Dual-tracer PET\/CT in renal angiomyolipoma and subtypes of renal cell carcinoma","volume":"37","author":"Ho","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.006_bib0029","doi-asserted-by":"crossref","first-page":"499","DOI":"10.15537\/smj.2019.5.24177","article-title":"Mixed epithelial and stromal tumor of the kidney on 18F-FDG PET\/CT in a 21-year-old female","volume":"40","author":"Tian","year":"2019","journal-title":"Saudi Med J"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.006_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5603\/NMR.2013.0002","article-title":"Role of F18-FDG-PET\/CT in restaging patients affected by renal carcinoma","volume":"16","author":"Bertagna","year":"2013","journal-title":"Nucl Med Rev Cent East Eur"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.006_bib0031","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00259-015-3159-6","article-title":"Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET\/CT","volume":"43","author":"Alongi","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.006_bib0032","doi-asserted-by":"crossref","first-page":"498","DOI":"10.5152\/dir.2022.21096","article-title":"Role of 18F-FDG PET\/CT for detection of recurrence and metastases in renal cell carcinoma\u2014are we underusing PET\/CT?","volume":"28","author":"Pereira","year":"2022","journal-title":"Diagn Interv Radiol"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0033","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"5S","key":"10.1053\/j.semnuclmed.2025.11.006_bib0034","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/j.jacr.2022.02.015","article-title":"(Expert Panel on Urological Imaging): ACR Appropriateness Criteria\u00ae post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma: 2021 update","volume":"19","author":"Purysko","year":"2022","journal-title":"J Am Coll Radiol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.006_bib0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.21873\/cdp.10097","article-title":"Efficacy of pre-operative 18F-FDG PET\/CT in prognostic prediction in patients with renal cell carcinoma","volume":"2","author":"Toguchi","year":"2022","journal-title":"Cancer Diagn Progn"},{"key":"10.1053\/j.semnuclmed.2025.11.006_bib0036","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/1471-2407-12-162","article-title":"Early assessment by FDG-PET\/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course","volume":"12","author":"Ueno","year":"2012","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.006_bib0037","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/MNM.0000000000001553","article-title":"Role of 18F-FDG PET\/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy","volume":"43","author":"Tatar","year":"2022","journal-title":"Nucl Med Commun"},{"issue":"20","key":"10.1053\/j.semnuclmed.2025.11.006_bib0038","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019988","article-title":"Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of 18F-FDG PET\/CT in patients with renal carcinoma: a protocol for systematic review and meta-analysis","volume":"99","author":"Xuan","year":"2020","journal-title":"Medicine"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.006_bib0039","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00259-008-0981-0","article-title":"11C-acetate PET imaging for renal cell carcinoma","volume":"36","author":"Oyama","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.006_bib0040","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2967\/jnumed.110.084517","article-title":"Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response\u2014an 18F-fluoromisonidazole PET\/CT study","volume":"52","author":"Hugonnet","year":"2011","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.006_bib0041","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3390\/jcm11071829","article-title":"PSMA PET\/CT in renal cell carcinoma: an overview of current literature","volume":"11","author":"Muselaers","year":"2022","journal-title":"J Clin Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:49:54Z","timestamp":1773845394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825001588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0001299825001588"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.006","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Any Role of FDG PET in Renal Cancer?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}